Form 4: Vertex CSO Altshuler Gains Shares from Performance Vesting

Vertex Pharmaceuticals' Chief Scientific Officer, David Altshuler, acquired 11,194 shares of common stock through the vesting of performance-based awards.

Summary

• David Altshuler, Executive Vice President and Chief Scientific Officer of Vertex Pharmaceuticals Inc. (VRTX), acquired a total of 11,194 shares of common stock.
• These shares were acquired on January 22, 2026, at a price of $0 per share, representing earned performance shares from previously granted performance stock unit (PSU) awards.
• A block of 7,866 shares relates to a PSU award granted on February 1, 2023, with these shares scheduled to vest on February 13, 2026.
• Another block of 3,328 shares relates to a PSU award granted on February 12, 2025, with these shares scheduled to vest in installments beginning on February 24, 2026.
• The issuer's management development and compensation committee certified the attainment of the performance goals for both awards on January 22, 2026.
• Following these transactions, David Altshuler directly beneficially owns 34,477 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The filing indicates a positive event where a key executive has earned and vested performance shares, reflecting the achievement of company goals and increasing insider ownership. This is a routine but positive signal regarding executive alignment and performance.

Positives

• Increased direct beneficial ownership by a key executive, David Altshuler, which aligns his interests more closely with those of shareholders.
• The vesting of performance shares indicates the successful attainment of pre-defined company performance goals, as certified by the compensation committee.

Future Outlook

NA

Management Comments

• The issuer's management development and compensation committee certified the level of performance-goal attainment on January 22, 2026, for the performance stock unit awards.

Industry Context

This filing reflects a standard practice in executive compensation within the pharmaceutical and biotechnology industry, where a significant portion of executive pay is tied to performance-based equity awards. Such awards are designed to incentivize long-term value creation and align management's interests with those of shareholders by linking compensation to specific operational or financial achievements.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholders due to higher direct equity ownership. The vesting indicates that performance targets, which likely benefit shareholders, have been met.
• Employees: May signal a positive internal environment where performance goals are being met, potentially boosting morale and confidence in leadership.

Next Steps

• Vesting of 7,866 performance shares on February 13, 2026.
• Vesting of 3,328 performance shares in installments beginning February 24, 2026.

Key Dates

Keywords

Vertex Pharmaceuticals, VRTX, David Altshuler, Chief Scientific Officer, CSO, Insider Transaction, Form 4, Performance Shares, Stock Vesting, Executive Compensation, Equity Award